Will is a Postdoctoral Research Associate in the Beall Group, where he is exploring the therapeutic potential of a unique type of brain cell for the treatment of type 1 diabetes. His research contributes to the development of novel, next-generation beta cell therapies aimed at restoring insulin production and achieving long-term disease remission.

Will trained as a Biomedical Engineer at Imperial College London before completing a PhD in Regenerative Medicine in 2021, where he focused on developing pericyte-engineered vascular grafts for the treatment of children with complex congenital heart disease. He then undertook a short-term postdoctoral position investigating the feasibility of AAV-based gene therapy for nephrotic syndrome.

Following this, Will spent three and a half years at eXmoor Pharma, a cell and gene therapy CDMO, where he led the upstream team in successfully delivering multiple projects for a diverse portfolio of advanced therapy clients.

Will has a passion for advanced therapies and utilising his skillset to drive translation of innovative research towards clinical application. Outside of the lab, he enjoys traveling and exploring the outdoors with his wife and dog —whether by foot, kayak, or campervan.